Dishman CarbogenQ2 FY25

Dishman Carbogen Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹130.34Market Cap: ₹2.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

No

Order

No

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Bavla site in India expects 25% to 30% growth in the next financial year, aiming to normalize operations and improve margins (Page 17).
  • Overall company revenue growth estimated around 8% to 9% for the full fiscal year (Page 9).
  • Carbogen Amcis targeting CHF 255 million revenue for FY '25 and is on track to achieve this (Page 8).
  • CRAMS Carbogen Amcis business saw a commercial revenue growth of about 52% compared to last year Q2 (Page 6).
  • Increase in inquiries and order books expected post-election, leading to new project capture in early 2025 (Pages 8, 9).
  • French facility expected to reach break-even in the next financial year with revenue growth from €9.5 million in H1 to €18-19 million next year (Page 9).
  • Long term goal to reach steady-state EBITDA margin of ~25-30% supported by improved operations in India, France, and reduction in raw material prices in Netherlands (Page 17).

See what Dishman Carbogen management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • No plans to raise equity to repay debt as per Harshil Dalal.
  • Interest rates (LIBOR/SOFR) are expected to decrease, reducing interest costs, making debt cheaper than equity.
  • The company will continue managing hedging actively to handle foreign currency exposure.
  • Focus is on generating free cash flow to reduce net debt over the next 2-2.5 years, targeting a net debt-to-EBITDA ratio below 2 by FY '27.
  • No mention of new debt fundraising; emphasis is on maintaining and reducing current debt levels through cash flow rather than new borrowings.

See what Dishman Carbogen management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Major capex related to growth has largely been completed; future capex will mainly be maintenance-focused.
  • Total capex in the first half of the financial year was about INR125 crores; expected full-year capex around INR250 crores, including digital transformation activities.
  • Discussions underway for a potential 2-digit million investment in a specific facility to debottleneck supply chain capacity, linked to a customer project ramp-up in the second half.
  • Continued investment in digitalization and operational excellence to improve efficiency and profitability.
  • No plans presently to raise equity for debt repayment; interest rates expected to decrease, reducing finance costs.

Track Dishman Carbogen — get its next earnings analysis in your feed

How does Dishman Carbogen rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisDishman Carbogen
Rev 3Mar 1

How does Dishman Carbogen rank in Pharmaceuticals & Biotechnology?

Compare Dishman Carbogen against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →